NCT04099277: A Study of LY3435151 in Participants With Solid Tumors |
|
|
| Terminated | 1a/1b | 2 | Japan, US | LY3435151, Pembrolizumab | Eli Lilly and Company | Solid Tumor, Triple-negative Breast Cancer, Gastric Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Cervical Carcinoma, High Grade Serous Ovarian Carcinoma, Hepatocellular Carcinoma, Undifferentiated Pleomorphic Sarcoma, Leiomyosarcoma | 03/20 | 03/20 | | |
